Guangdong Province Aims for RMB One Trillion in Biopharma Industry Growth by 2027
The People’s Government of Guangdong Province has unveiled an ambitious “Action Plan for Further Promoting...
Immupeutics Medicine Secures NMPA Approval for Personalized Liver Cancer Immunotherapy IPM001
Immupeutics Medicine, a pioneer in tumor immunotherapy based in Beijing, has announced that it has...
Eli Lilly & Co. Partners with Insitro to Leverage AI in Metabolic Disease Drug Development
Eli Lilly & Co. (NYSE: LLY), a stalwart of the US pharmaceutical industry, has inked...
Pfizer’s Hympavzi Secures FDA Nod, Offering Novel Once-Weekly Treatment for Hemophilia B
Pfizer Inc. (NYSE: PFE) has scored a significant win with the US Food and Drug...
Hetero and Gilead Sciences Partner to Expand Access to HIV Treatment in Low-Income Countries
Indian pharmaceutical company Hetero has announced a new partnership with US healthcare giant Gilead Sciences...
Huadong Medicine Secures NMPA Approval for Semaglutide Biosimilar, Aims to Capture Weight Loss Market
Nanjing-based Huadong Medicine Co., Ltd (SHE: 000963) has received clinical trial approval from China’s National...
Coherent Biopharma’s CBP-1008 Earns FDA Fast Track for Platinum-Resistant Ovarian Cancer
Coherent Biopharma Ltd, a specialist in bispecific-ligand drug conjugates (Bi-XDCs) with operations in Suzhou, China,...
Doma Biopharmaceutical Receives Green Light for Clinical Trial of Novel ADC DM001 Targeting Solid Tumors
Doma Biopharmaceutical (Suzhou) Co., Ltd, a biotech firm with a presence in China and the...
Harbour BioMed’s Innovative Antibody Porustobart Shows Promise in Early Clinical Trials for Melanoma
Harbour BioMed (HKG: 2142), a biopharmaceutical company with operations in the United States, the Netherlands,...
Eli Lilly Expands Collaboration with KeyBioscience to Develop Obesity Treatments Using DACRA Platform
Eli Lilly and Company (NYSE: LLY) has announced an extension of its collaboration with KeyBioscience...
XtalPi’s AI Platform XtalFold Secures Licensing Deal with Janssen Biotech, Enhancing Biologics Discovery
XtalPi (QuantumPharm, HKG: 2228) a leading AI-driven drug discovery firm based in Shenzhen and known...
Roche’s Genentech Scores FDA Approval for Itovebi in Advanced Breast Cancer Treatment, Advancing Personalized Oncology
Roche (SWX: ROG)’s Genentech, a leader in pharmaceutical innovation, has received approval from the US...
Johnson & Johnson’s Darzalex Combo Therapy Gets EMA Nod for Multiple Myeloma, Aims to Set New Standard
Johnson & Johnson (NYSE: JNJ) has taken a significant step in expanding its oncology portfolio...
Jiangsu Hengrui’s SHR2554 Gets Priority Review for Lymphoma Treatment, Strengthening Global EZH2 Inhibitor Market
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) is on the brink of a breakthrough in...
Jiangsu Hengrui Secures FDA Nod for Generic Abraxane, Strengthening Oncology Portfolio
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has achieved a first in the US market...
Roche’s VENTANA CLDN18 Assay Receives EU Approval, Enhances Targeted Therapy Options for Gastric Cancer
Roche (SWX: ROG; OTCMKTS: RHHBY) has secured CE Mark approval in the European Union for...
Biogen Gains FDA Breakthrough Status for Felzartamab in Kidney Transplant Rejection Treatment
Biogen Inc. (NASDAQ: BIIB) has secured breakthrough therapy designation (BTD) from the U.S. Food and...
Eli Lilly & Co. Boosts Suzhou Plant with $211M to Meet Diabetes and Obesity Drug Demand
Eli Lilly & Co.(NYSE: LLY)’s China subsidiary is poised to invest a substantial RMB 1.5...
China’s NMPA Proposes Rewards for Internal Whistleblowers in Drug and Medical Device Safety Reporting
The National Medical Products Administration (NMPA) of China has issued a draft proposal for the...
Sunvozertinib’s Companion Diagnostic Gets NMPA Nod, Fortifying Targeted Therapy Arsenal for NSCLC in China
Dizal Pharmaceutical Co., Ltd (SHA: 688192) and Burning Rock Ltd (NASDAQ: BNR, FRA: 6BU0) have...